Repligen (NASDAQ:RGEN) Sees Large Volume Increase – Still a Buy?

Shares of Repligen Corporation (NASDAQ:RGEN) saw unusually-strong trading volume on Wednesday . 563,554 shares were traded during trading, a decline of 42% from the previous session’s volume of 971,611 shares.The stock last traded at $140.69 and had previously closed at $136.99.

Repligen News Summary

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Repligen said it will acquire BioLife Solutions for about $1.5 billion in cash and stock, a move that expands its presence in the fast-growing cell therapy market and adds BioLife’s biopreservation media and cell-processing tools to Repligen’s portfolio. Article Title
• Positive Sentiment: Management said the deal should be accretive to Repligen’s adjusted earnings per share by at least $0.05 in year one and $0.25 in year two, with expected synergies of at least $20 million in year one and $30 million in year two. Article Title
• Neutral Sentiment: Repligen also reported preliminary Q2 revenue growth of about 12% as reported and 13% organically, signaling continued operating growth ahead of its full earnings release next week. Article Title
• Negative Sentiment: Some analysts and market commentary flagged concerns that the acquisition may cap upside for BioLife and could dilute existing Repligen shareholders because the deal is mostly stock-based and still needs regulatory and shareholder approvals. Article Title

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on RGEN shares. JPMorgan Chase & Co. cut their target price on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Roth Capital began coverage on Repligen in a report on Friday, April 17th. They set a “buy” rating and a $160.00 price target on the stock. Royal Bank Of Canada started coverage on Repligen in a research note on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price target on the stock. HSBC cut their price objective on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Finally, Weiss Ratings raised Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, July 14th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $165.36.

Repligen Trading Up 2.7%

The firm has a market capitalization of $7.94 billion, a PE ratio of 156.46, a PEG ratio of 2.80 and a beta of 1.06. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. The stock’s fifty day simple moving average is $129.75 and its 200 day simple moving average is $132.96.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.10. The business had revenue of $194.25 million for the quarter, compared to the consensus estimate of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period last year, the firm earned $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, sell-side analysts predict that Repligen Corporation will post 1.99 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. The trade was a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.60% of the company’s stock.

Institutional Trading of Repligen

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC purchased a new stake in Repligen in the 1st quarter worth approximately $262,000. Jones Financial Companies Lllp lifted its holdings in Repligen by 3,850.6% during the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after purchasing an additional 6,238 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Repligen by 16.8% during the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after purchasing an additional 20,375 shares in the last quarter. Bank of Nova Scotia boosted its position in shares of Repligen by 88.0% in the second quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock worth $3,951,000 after purchasing an additional 14,860 shares during the period. Finally, Daiwa Securities Group Inc. boosted its position in shares of Repligen by 29.7% in the second quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock worth $3,880,000 after purchasing an additional 7,148 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.